BioTuesdays

Tag - AUP

Aurinia readies Phase 2b trial in lupus nephritis

Aurinia Pharmaceuticals (TSX-V:AUP) is preparing to begin a Phase 2b clinical trial in the first quarter of 2014 with its voclosporin immunosuppressant in combination with CellCept, the standard of care for treating...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.